Spondyloarthritis & psoriatic arthritis
The lack of association between cumulative MTX dose and liver fibrosis in PsA: a cohort study
Authors' conclusion
Metabolic factors, rather than the cumulative MTX dose, are associated with liver fibrosis in PsA.
Study context
- Population
- Patients with PsA in a prospective observational cohort (mean age 44.4 [SD 13.1] at baseline)
- Participants
- 1,314 patients
- Exposure
- Cumulative MTX dose and metabolic factors vs liver fibrosis
- Outcome
- Liver fibrosis per APRI (cut-off >0.7); association with cumulative MTX dose and metabolic factors
Methodological detailsobservational, multivariable GEE analysis
- Observational
- Multivariable GEE analysis
Main finding
As reported in the abstract
Liver fibrosis (APRI >0.7), multivariable model
Cumulative MTX dose, adjusted OR (95% CI 0.98-1.01); not independently associated
0.99
Higher BMI, adjusted OR
1.03
95% CI 1.00–1.05
Diabetes mellitus, adjusted OR
5.03
95% CI 2.19–11.56
Observational data: associations, not effects.
Further findings
Frequency of liver fibrosis per aminotransferase to platelet ratio index (APRI)
- At baseline, n (%)
- 44 (3.3%)
- Developed during follow-up, n (%)
- 154 (11.7%)
- Median time to fibrosis from baseline, years [IQR 2.0-11.1]
- 5.6
MTX exposure
- Receiving MTX at baseline, n (%)
- 375 (28.5%)
- Ever received MTX, n (%)
- 763 (58.1%)
Original publication
The lack of association between cumulative MTX dose and liver fibrosis in PsA: a cohort study. Rheumatology (Oxford). Published 23 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →